TScan Pauses Key Trials, Shifts Focus to Solid Tumors

TScan paused enrollment in the Phase 3 ALLOHA-2 study due to insufficient capital; the company is reorganizing to focus resources on developing two in vivo-engineered TCR-T candidates for solid tumors. Stock reaction: PURSUANT TO RULE 11a-3 UNDER THE ACT: THIS IS AN ANNOUNCEMENT NOT REQUIRE FILING UNDER THE ACT; 8-K